NASDAQ:COYA Coya Therapeutics (COYA) Stock Price, News & Analysis $4.75 +0.11 (+2.37%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Coya Therapeutics Stock (NASDAQ:COYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coya Therapeutics alerts:Sign Up Key Stats Today's Range$4.57▼$4.9450-Day Range$3.99▼$5.2652-Week Range$3.71▼$7.75Volume102,818 shsAverage Volume180,910 shsMarket Capitalization$111.30 millionP/E RatioN/ADividend YieldN/APrice Target$15.33Consensus RatingModerate Buy Company Overview Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments. Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors. The company employs a proprietary screening platform to identify and optimize compounds that selectively bind or inhibit UNC-45A in diseased tissues, while minimizing off-target effects in healthy cells. In addition to its internal research, Coya has established collaborations with academic and industry partners to accelerate translational studies and position its candidates for clinical entry. Headquartered in Boston, Massachusetts, Coya Therapeutics leverages a multidisciplinary team of scientists with expertise in molecular biology, medicinal chemistry and translational medicine. The company is committed to advancing its pipeline through proof‐of‐concept studies, with the goal of delivering novel therapies that improve outcomes for patients suffering from high‐unmet‐need fibrotic and oncologic indications. Coya’s strategic focus on mechanistic innovation seeks to create durable treatment options where current standards of care are limited.AI Generated. May Contain Errors. Read More Coya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreCOYA MarketRank™: Coya Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 443rd out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCoya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCoya Therapeutics has a consensus price target of $15.33, representing about 220.0% upside from its current price of $4.79.Amount of Analyst CoverageCoya Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Coya Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.49) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coya Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coya Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoya Therapeutics has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Coya Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.18% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 8.84.Change versus previous monthShort interest in Coya Therapeutics has recently increased by 12.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoya Therapeutics does not currently pay a dividend.Dividend GrowthCoya Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.48 News SentimentCoya Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Coya Therapeutics this week, compared to 3 articles on an average week.Search Interest5 people have searched for COYA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coya Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.10% of the stock of Coya Therapeutics is held by insiders.Percentage Held by Institutions39.75% of the stock of Coya Therapeutics is held by institutions.Read more about Coya Therapeutics' insider trading history. Receive COYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COYA Stock News HeadlinesCoya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impactJune 10 at 5:14 PM | finance.yahoo.comCoya Therapeutics begins extension phase of ALSTARS trial for COYA 302June 9 at 10:54 AM | yahoo.comPlease open before June 12!The SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.June 12 at 1:00 AM | InvestPub (Ad)Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension PhaseJune 8, 2026 | finance.yahoo.comCoya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 7, 2026 | americanbankingnews.comCoya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development SummitMay 28, 2026 | uk.finance.yahoo.comCoya Therapeutics secures FDA fast track status for COYA 302May 14, 2026 | finance.yahoo.comCoya Therapeutics Inc COYAMay 12, 2026 | morningstar.comMSee More Headlines COYA Stock Analysis - Frequently Asked Questions How have COYA shares performed this year? Coya Therapeutics' stock was trading at $5.80 at the beginning of the year. Since then, COYA stock has decreased by 17.4% and is now trading at $4.7910. How were Coya Therapeutics' earnings last quarter? Coya Therapeutics, Inc. (NASDAQ:COYA) issued its earnings results on Tuesday, May, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.15 million. Coya Therapeutics had a negative trailing twelve-month return on equity of 55.86% and a negative net margin of 266.10%. When did Coya Therapeutics IPO? Coya Therapeutics (COYA) raised $15 million in an IPO on Thursday, December 29th 2022. The company issued 3,050,000 shares at $5.00 per share. Who are Coya Therapeutics' major shareholders? Coya Therapeutics' top institutional shareholders include Renaissance Technologies LLC (0.44%), Dimensional Fund Advisors LP (0.41%), ADAR1 Capital Management LLC (0.17%) and Cetera Investment Advisers (0.13%). Insiders that own company stock include David S Snyder, Arun Swaminathan and Fred Grossman. View institutional ownership trends. How do I buy shares of Coya Therapeutics? Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/12/2026Today6/12/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 COYA's financial health is in the Red zone, according to TradeSmith. COYA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COYA CIK1835022 Webwww.coyatherapeutics.com Phone800-587-8170FaxN/AEmployees6Year Founded2016Price Target and Rating Average Price Target for Coya Therapeutics$15.33 High Price Target$18.00 Low Price Target$12.00 Potential Upside/Downside+223.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.23 million Net Margins-266.10% Pretax Margin-266.07% Return on Equity-55.86% Return on Assets-48.86% Debt Debt-to-Equity RatioN/A Current Ratio15.02 Quick Ratio15.02 Sales & Book Value Annual Sales$7.94 million Price / Sales14.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book2.30Miscellaneous Outstanding Shares23,457,000Free Float22,026,000Market Cap$111.30 million OptionableNot Optionable Beta0.62 Social Links Missed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:COYA) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersSMX Could Turn Proof Technology into Major Profit!SMX (Security Matters) PLC embeds invisible molecular markers into plastics, metals, fuels, and textiles, link...Smallcaps Daily | SponsoredVWAV: Is This the Next Defense Breakout?VisionWave Holdings, Inc. (NASDAQ: VWAV) is developing a full-stack defense technology platform that integrate...Equiscreen | SponsoredPhysical gold in your 401k - what Wall Street already knowsOn March 30th, the Department of Labor quietly filed a rule allowing physical gold to be held inside an eligib...Cedar Gold Group | SponsoredThis Is How Financial Freedom Dies—And Most People Never See It ComingWhile the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...Priority Gold | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
